Soluble interleukin-7 receptor (sIL7R) modulation therapy for the treatment of autoimmune diseases and cancer

SM-ASOs modulate IL7R splicing to address autoimmune diseases and cancer by reducing sIL7R in autoimmune diseases and increasing it in cancer, offering safer and more effective treatments.

JP7576835B2Active Publication Date: 2024-11-01BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020550763
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-03-22
Filing Date
2019-03-22
Publication Date
2024-11-01
Estimated Expiration
2039-03-22

AI Technical Summary

Technical Problem

Current treatments for autoimmune diseases like multiple sclerosis and cancer are limited by severe side effects from global immunosuppression and low response rates to immunotherapy, respectively, necessitating a targeted approach to address specific disease pathogenesis.

Method used

Development of splice-regulated antisense oligonucleotides (SM-ASOs) that modulate the splicing of interleukin-7 receptor (IL7R) pre-mRNA to either reduce or increase the expression of the soluble isoform (sIL7R), using specific sequences to target exon 6 inclusion or exclusion, thereby addressing the root cause of these diseases.

Benefits of technology

The SM-ASOs effectively reduce sIL7R levels in autoimmune diseases without immunosuppression, enhancing immune response in cancer, thus providing safer and more effective treatments for both conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007576835000005
    Figure 0007576835000005
  • Figure 0007576835000006
    Figure 0007576835000006
  • Figure 0007576835000007
    Figure 0007576835000007
Patent Text Reader

Abstract

The present invention includes compositions and methods for treating autoimmune disorders or cancer in a subject in need thereof, the methods comprising administering an effective amount of a composition comprising an oligonucleotide that specifically binds to a complementary sequence of interleukin-7 receptor (IL7R) pre-mRNA that affects the splicing of exon 6, wherein the SM-ASO increases or decreases the inclusion of exon 6 in the IL7R pre-mRNA, thereby decreasing or increasing the expression of the soluble isoform of IL7R (sIL7R), respectively. In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO) or a splice-modulating antisense oligonucleotide (SM-ASO). [Selected figure] Figure 7B
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS none.

[0002] Statement on Federally Sponsored Research This invention was made with government support under F32-NS087899 awarded by the NIH. The United States Government has certain rights in the invention.

[0003] FIELD OF THEINVENTION The present invention relates generally to novel therapies that decrease or increase soluble IL7R (sIL7R) to treat autoimmune diseases (e.g., multiple sclerosis) or cancer, respectively. [Background technology]

[0004] Without limiting the scope of the invention, its background is described in the context of multiple sclerosis, by way of example only.

[0005] Multiple sclerosis (MS) is a chronic autoimmune disease characterized by autoreactive immune cell-mediated damage to nerve myelin sheaths in the central nervous system (CNS) that leads to axonal demyelination, neuronal death and progressive neurological dysfunction. To date, there is no cure for the disease, and available treatments can only slow disease progression, often by globally suppressing the immune system, causing numerous adverse side effects that can be severe and potentially fatal. This global immune suppression is a major limitation of current therapies.

[0006] The breakdown of immune tolerance that leads to MS is thought to be due to a complex interplay between environmental and genetic factors. According to this view, an individual's genetic background generates an environment that allows the survival of autoreactive lymphocytes, which can then be activated by the presence of an environmental stimulus, usually in the form of a viral or bacterial infection.

[0007] We and others have previously shown that the variant rs6897932 (C / T, where C is the risk allele) in exon 6 of the interleukin-7 receptor (IL7R) gene is strongly associated with increased MS risk (Gregory et al., 2007; International Multiple Sclerosis Genetics et al., 2007; Lundmark et al., 2007). Furthermore, we have shown that the risk "C" allele of this variant increases exon skipping (Evsyukova et al., 2013; Gregory et al., 2007), leading to increased expression of sIL7R (Hoe et al., 2010; Lundstrom et al., 2013). Importantly, sIL7R was shown to exacerbate the clinical progression and severity of disease in an experimental autoimmune encephalomyelitis (EAE) MS mouse model, likely by enhancing the bioavailability and / or bioactivity of IL7 cytokines (Lundstrom et al., 2013).Further supporting a role for sIL7R in the pathogenesis of multiple sclerosis, and possibly autoimmunity in general, high levels of sIL7R protein or RNA have been reported in patients with multiple sclerosis (McKay et al. 2008), rheumatoid arthritis (Badot et al., 2011), type 1 diabetes (Monti et al., 2013), and systemic lupus erythematosus (Lauwerys et al., 2014). Overall, these data link high levels of sIL7R to the pathogenesis of MS and autoimmunity and position alternative splicing of IL7R exon 6 as a novel therapeutic target for MS and autoimmunity.

[0008] Although these documents teach that the presence of sIL7R is associated with multiple sclerosis, and animal studies indicate that sIL7R exacerbates MS-like conditions, there remains a need for novel compositions and methods for treating autoimmune diseases such as MS by targeting the production of sIL7R.

[0009] There are many different etiologies for autoimmune diseases, each of which may be a target for precise or individualized therapy. In this invention, we address one such etiology, which is caused by high levels of sIL7R, which may affect up to 60% of MS patients and a large number of patients with other autoimmune disorders caused by high sIL7R.

[0010] Cancer immunotherapy is a rapidly expanding field that holds great promise for patients with previously difficult-to-control cancers; however, the effectiveness of immunotherapy is limited by extremely low response rates in some cancers and individuals.

[0011] Antisense oligonucleotide therapy targets genetic sequences of specific genes responsible for a particular disease using short oligonucleotides complementary to the target sequence. Typically, a strand of nucleic acid is designed (DNA, RNA or chemical analogues) that binds to the messenger RNA (mRNA) or pre-mRNA of the target sequence. In the case of splice-regulatory antisense oligonucleotides (SM-ASOs), the complementary nucleic acid is designed to bind to a specific sequence in the pre-mRNA that regulates the exon content of the resulting mRNA. Antisense oligonucleotides have been used to target diseases such as cancer, diabetes, amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, spinal muscular atrophy, ataxia telangiectasia, asthma, and arthritis. Several antisense oligonucleotide drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cytomegalovirus retinitis, homozygous familial hypercholesterolemia, Duchenne muscular dystrophy, and spinal muscular atrophy, to name a few. The latter two are SM-ASOs. In each case, however, the oligonucleotide target sequence must be tailored to the specific underlying etiology of the disease. Summary of the Invention

[0012] In one embodiment, the present invention includes a method of treating a disease or condition associated with high levels of soluble isoform of interleukin 7 receptor (sIL7R) in a subject in need thereof, the method comprising administering an effective amount of a composition comprising an oligonucleotide that specifically binds to a sequence of interleukin 7 receptor (IL7R) pre-mRNA that affects the splicing of exon 6, which oligonucleotide increases the inclusion of exon 6 in IL7R pre-mRNA and reduces the expression of soluble isoform of IL7R (sIL7R). In one aspect, the oligonucleotide is an antisense oligonucleotide (ASO) or a splice-modulating antisense oligonucleotide (SM-ASO). In another aspect, the oligonucleotide in the composition specifically binds to a sequence in IL7R pre-mRNA in at least one of the group consisting of exonic splicing suppressor sequences (ESS) and / or intronic splicing suppressor sequences (ISS), thereby increasing the inclusion of exon 6 in IL7R pre-mRNA and reducing the expression of sIL7R. In another embodiment, the oligonucleotide in the composition specifically binds to a sequence on the IL7R pre-mRNA at an intron-exon splice site, a branch point sequence, and / or a polypyrimidine tract.In another embodiment, at least one or more nucleotides in the oligonucleotide contain a non-natural modification, including a modification or substitution of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, selected from the following: one or more phosphorothioates, dithiophosphates, phosphodiesters, methylphosphonates, phosphoramidates, methylphosphonates, phosphotriesters, phosphoroaridates, morpholinos, amidate carbamates, carbamate), carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbone, locked nucleic acid backbone, peptide backbone, phosphotriester backbone, phosphoramidate backbone, siloxane backbone, carboxymethyl ester backbone, acetamidate backbone, carbamate backbone, thioether backbone, bridged methylene phosphonate backbone, phosphorothioate backbone, methyl phosphonate backbone, alkyl phosphonate backbone, phosphate ester backbone, methyl phosphorothioate backbone, alkyl phosphonothioate backbone, phosphatase backbone, Partially or fully modified backbones such as holodithioate backbones, carbonate backbones, phosphate triester backbones, carboxymethyl ester backbones, methyl phosphorothioate backbones, phosphorodithioate backbones, backbones with p-ethoxy linkages; sugar modifications such as 2'-O-methyl (2'-O-methyl nucleotides), 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties, or bicyclic sugar moieties; nucleotide mimetics, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids, and locked nucleic acids (LNAs), as well as combinations of two or more of any of the foregoing. In another embodiment, at least one or more nucleotides in the oligonucleotide comprises a non-natural modification to the nucleotide base.In another embodiment, the oligonucleotide is selected from any of the sequences in Table 1 (SEQ ID NOs: 1-13), or portions thereof, alone or in combination, or from sequences having at least 70, 75, 80, 84, 85, 88, 92, 93, 94, 95, or 96% identity to the entire target sequence within the IL7R RNA. In another embodiment, the oligonucleotide targets any of the sequences in Table 1 (SEQ ID NOs: 1-13), in whole or in part. In another embodiment, the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier. In another embodiment, the disease or condition is an autoimmune disorder selected from at least one of the following: multiple sclerosis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, ankylosing spondylitis, primary biliary cirrhosis, or inflammatory bowel syndromes such as ulcerative colitis, Crohn's disease, or any other condition in which sIL7R is elevated compared to normal subjects without the disease or condition. In another embodiment, the disease or condition is an inflammatory disease or condition. In another aspect, the oligonucleotide enhances the degradation of IL7R mRNA lacking exon 6 by targeting the IL7R exon 5 to exon 7 boundary, for example, with an ASO, siRNA, shRNA that reduces the stability (e.g., increases degradation) of sIL7R RNA, and / or with an ASO that reduces the translation of sIL7R RNA. In another aspect, the method further includes combination therapy of the SM-ASO with one or more active agents effective in treating an autoimmune disease, such as, but not limited to, mitoxatrone, interferon beta 1a, PEG-interferon beta 1a, azathioprine, fingolimod, natalizumab, methylprednisolone, or ocrelizumab. In another aspect, the method further comprises obtaining cells from the patient and modifying the cells to transiently or permanently express an oligonucleotide that specifically binds to a sequence in interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6.In another embodiment, the method further comprises generating a vector expressing an oligonucleotide that specifically binds to a sequence in interleukin-7 receptor (IL7R) pre-mRNA that affects splicing of exon 6 for use in gene therapy, and treating a patient with the vector.

[0013] In another embodiment, the invention includes a composition comprising an oligonucleotide that is an antisense oligonucleotide (ASO) or splice modifier antisense oligonucleotide (SM-ASO), which specifically binds to a sequence in the pre-mRNA of interleukin-7 receptor (IL7R) that affects the splicing of exon 6, and the SM-ASO increases the inclusion of exon 6 in the IL7R pre-mRNA and reduces the expression of the soluble isoform of IL7R (sIL7R). In one aspect, the oligonucleotide in the composition specifically binds to a sequence in the IL7R pre-mRNA at at least one of the group consisting of an exonic splicing suppressor sequence (ESS) and / or an intronic splicing suppressor sequence (ISS), thereby increasing the inclusion of exon 6 in the IL7R pre-mRNA and reducing the expression of sIL7R. In another aspect, the oligonucleotide in the composition specifically binds to a sequence on the IL7R pre-mRNA at an intron-exon splice site, a branch point sequence, and / or a polypyrimidine tract.In another embodiment, at least one or more nucleotides in the oligonucleotide contain a non-natural modification, including a modification or substitution of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, selected from the following: one or more phosphorothioates, dithiophosphates, phosphodiesters, methylphosphonates, phosphoramidates, methylphosphonates, phosphotriesters, phosphoroaridates, morpholinos, amidate carbamates, carbamate), carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbone, locked nucleic acid backbone, peptide backbone, phosphotriester backbone, phosphoramidate backbone, siloxane backbone, carboxymethyl ester backbone, acetamidate backbone, carbamate backbone, thioether backbone, bridged methylene phosphonate backbone, phosphorothioate backbone, methyl phosphonate backbone, alkyl phosphonate backbone, phosphate ester backbone, methyl phosphorothioate backbone, alkyl phosphonothioate backbone, phosphorothioate backbone, Partially or fully modified backbones such as dithioate backbones, carbonate backbones, phosphate triester backbones, carboxymethyl ester backbones, methyl phosphorothioate backbones, phosphorodithioate backbones, backbones with p-ethoxy linkages; sugar modifications such as 2'-O-methyl (2'-O-methyl nucleotides), 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties, or bicyclic sugar moieties; nucleotide mimetics, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids, and locked nucleic acids (LNAs), as well as any combination of two or more of any of the foregoing. In another embodiment, at least one or more nucleotides in the oligonucleotide comprises a non-natural modification to the nucleotide base.In another embodiment, the oligonucleotide is selected from any of the sequences in Table 1 (SEQ ID NOs: 1-13), or portions thereof, alone or in combination, or from sequences having at least 70, 75, 80, 84, 85, 88, 92, 93, 94, 95, or 96% identity to the entire target sequence in the IL7R RNA. In another embodiment, the oligonucleotide targets any of the sequences in Table 1 (SEQ ID NOs: 1-13), in whole or in part. In another embodiment, the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier. In another embodiment, the composition is suitable for the treatment of an autoimmune disorder selected from at least one of the following: multiple sclerosis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, ankylosing spondylitis, primary biliary cirrhosis, or inflammatory bowel syndromes such as ulcerative colitis and Crohn's disease, or any other condition in which sIL7R is elevated. In another embodiment, the oligonucleotide enhances degradation of IL7R mRNA lacking exon 6 by targeting the IL7R exon 5 to exon 7 boundary, e.g., using an ASO, siRNA, shRNA that reduces the stability of sIL7R RNA (e.g., increasing degradation) and / or using an ASO that reduces translation of sIL7R RNA.

[0014] In yet another embodiment, the invention includes a method of increasing inclusion of exon 6 in an interleukin 7 receptor (IL7R) pre-mRNA, the method comprising contacting with a splice modifier antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in the interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6, the SM-ASO increasing inclusion of exon 6 in the IL7R pre-mRNA and decreasing expression of a soluble isoform of IL7R (sIL7R). In one aspect, the SM-ASO in the composition specifically binds to a sequence in the IL7R pre-mRNA at at least one of the group consisting of an exonic splicing suppressor sequence (ESS) and / or an intronic splicing suppressor sequence (ISS), thereby increasing inclusion of exon 6 in the IL7R pre-mRNA and decreasing expression of sIL7R. In another aspect, the SM-ASO in the composition specifically binds to a sequence on the IL7R pre-mRNA at an intron-exon splice site, a branch point sequence, and / or a polypyrimidine tract.In another embodiment, at least one or more nucleotides in the SM-ASO contain a non-natural modification, including a modification or substitution of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, selected from the following: one or more phosphorothioates, dithiophosphates, phosphodiesters, methylphosphonates, phosphoramidates, methylphosphonates, phosphotriesters, phosphoroaridates, morpholinos, amidate carbamates, carbamate), carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbone, locked nucleic acid backbone, peptide backbone, phosphotriester backbone, phosphoramidate backbone, siloxane backbone, carboxymethyl ester backbone, acetamidate backbone, carbamate backbone, thioether backbone, bridged methylene phosphonate backbone, phosphorothioate backbone, methyl phosphonate backbone, alkyl phosphonate backbone, phosphate ester backbone, methyl phosphorothioate backbone, alkyl phosphonothioate backbone, phosphorothioate backbone, partially or fully modified backbones such as dithioate backbones, carbonate backbones, phosphate triester backbones, carboxymethyl ester backbones, methyl phosphorothioate backbones, phosphorodithioate backbones, backbones having p-ethoxy linkages; sugar modifications such as 2'-O-methyl (2'-O-methyl nucleotides), 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties, or bicyclic sugar moieties; nucleotide mimetics, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids, and locked nucleic acids (LNAs), as well as any combination of two or more of any of the foregoing. In another embodiment, at least one or more nucleotides in the SM-ASO comprises a non-natural modification to the nucleotide base.In another embodiment, the SM-ASO enhances degradation of IL7R mRNA lacking exon 6 by targeting the IL7R exon 5 to exon 7 boundary, for example, with an ASO, siRNA, shRNA that reduces the stability (e.g., increases degradation) of sIL7R RNA, and / or with an ASO that reduces translation of sIL7R RNA. In another embodiment, the SM-ASO blocks translation of IL7R mRNA lacking exon 6. In another embodiment, the SM-ASO is selected from any of the sequences in Table 1 (SEQ ID NOs: 1-13), or a portion thereof, alone or in combination, or from sequences having at least 70, 75, 80, 84, 85, 88, 92, 93, 94, 95, or 96% identity to all target sequences within the IL7R RNA. In another embodiment, the oligonucleotide targets any of the sequences in Table 1 (SEQ ID NOs: 1-13), in whole or in part. In another embodiment, the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier. In another embodiment, the autoimmune disorder is selected from at least one of the following: multiple sclerosis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, ankylosing spondylitis, primary biliary cirrhosis, or inflammatory bowel syndromes such as ulcerative colitis and Crohn's disease, or any condition in which sIL7R is elevated. In another embodiment, the method further comprises obtaining cells from the patient and modifying the cells to express, either transiently or permanently, an oligonucleotide that specifically binds to a sequence of interleukin 7 receptor (IL7R) pre-mRNA that affects exon 6 splicing. In another embodiment, the method further comprises generating a vector expressing an oligonucleotide that specifically binds to a sequence of interleukin 7 receptor (IL7R) pre-mRNA that affects exon 6 splicing for use in gene therapy, and treating the patient with the vector.

[0015] In another embodiment, the invention includes a composition for increasing inclusion of exon 6 in interleukin 7 receptor (IL7R) pre-mRNA, the method comprising contacting with a splice-modifying antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6, where the SM-ASO increases inclusion of exon 6 in IL7R pre-mRNA and reduces expression of a soluble isoform of IL7R (sIL7R). In one aspect, the method further comprises combination therapy of the SM-ASO with one or more active agents effective in treating an autoimmune disease selected from, but not limited to, mitoxatrone, interferon beta 1a, PEG-interferon beta 1a, azathioprine, fingolimod, natalizumab, methylprednisolone, or ocrelizumab.

[0016] In another embodiment, the invention includes a vector expressing a nucleic acid comprising an oligonucleotide that is an antisense oligonucleotide (ASO) or a splice-modifying antisense oligonucleotide (SM-ASO), which specifically binds to a sequence in the interleukin-7 receptor (IL7R) pre-mRNA that affects the splicing of exon 6, where the SM-ASO increases the inclusion of exon 6 in the IL7R pre-mRNA and reduces expression of the soluble isoform of IL7R (sIL7R). In one aspect, the vector is a viral vector or a plasmid.

[0017] In another embodiment, the invention comprises a vector expressing a nucleic acid comprising an antisense oligonucleotide (ASO), splice modulating antisense oligonucleotide (SM-ASO), translation blocking antisense oligonucleotide, siRNA, shRNA or miRNA that specifically binds to a sequence in interleukin-7 receptor (IL7R) pre-mRNA that enhances the suppression or degradation of IL7R RNA lacking exon 6, wherein the nucleic acid reduces expression of a soluble isoform of IL7R (sIL7R). In one aspect, the vector is a viral vector or a plasmid.

[0018] In another embodiment, the present invention includes a method of treating multiple sclerosis in a subject in need thereof, the method comprising administering an effective amount of a composition comprising a splice-modulating antisense oligonucleotide (SM-ASO) that specifically binds to a sequence of interleukin 7 receptor (IL7R) pre-mRNA that affects the splicing of exon 6, wherein the SM-ASO increases the inclusion of exon 6 in the IL7R pre-mRNA and reduces the expression of a soluble isoform of IL7R (sIL7R) in a pharma- ceutically acceptable excipient. In one aspect, the method further comprises combination therapy of the SM-ASO with one or more active agents effective for treating multiple sclerosis. In another aspect, the one or more agents for treating multiple sclerosis are selected from, but not limited to, mitoxatrone, interferon beta 1a, PEG-interferon beta 1a, azathioprine, fingolimod, natalizumab, methylprednisolone, or ocrelizumab.

[0019] In another embodiment, the invention includes a method of treating cancer in a subject in need thereof, the method comprising administering an effective amount of a composition comprising an oligonucleotide that specifically binds to a sequence of interleukin 7 receptor (IL7R) pre-mRNA that affects the splicing of exon 6, the oligonucleotide reduces the inclusion of exon 6 in IL7R pre-mRNA and increases the expression of soluble isoform of IL7R (sIL7R). In one aspect, the oligonucleotide is an antisense oligonucleotide (ASO) or a splice-modulating antisense oligonucleotide (SM-ASO). In another aspect, the oligonucleotide in the composition specifically binds to a sequence in IL7R pre-mRNA of at least one of the group consisting of an exonic splicing enhancer sequence (ESE) and / or an intronic splicing enhancer sequence (ISE), thereby reducing the inclusion of exon 6 and increasing the expression of sIL7R. In another aspect, the oligonucleotide in the composition specifically binds to a sequence on IL7R pre-mRNA at an intron-exon splice site, a branch point sequence, and / or a polypyrimidine tract.In another embodiment, at least one or more nucleotides in the oligonucleotide contain a non-natural modification, including a modification or substitution of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, selected from the following: one or more phosphorothioates, dithiophosphates, phosphodiesters, methylphosphonates, phosphoramidates, methylphosphonates, phosphotriesters, phosphoroaridates, morpholinos, amidate carbamates, carbamate), carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbone, locked nucleic acid backbone, peptide backbone, phosphotriester backbone, phosphoramidate backbone, siloxane backbone, carboxymethyl ester backbone, acetamidate backbone, carbamate backbone, thioether backbone, bridged methylene phosphonate backbone, phosphorothioate backbone, methyl phosphonate backbone, alkyl phosphonate backbone, phosphate ester backbone, methyl phosphorothioate backbone, alkyl phosphonothioate backbone, phosphatase backbone, Partially or fully modified backbones such as holodithioate backbones, carbonate backbones, phosphate triester backbones, carboxymethyl ester backbones, methyl phosphorothioate backbones, phosphorodithioate backbones, backbones with p-ethoxy bonds; sugar modifications such as 2'-O-methyl (2'-O-methyl nucleotides), 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties, or bicyclic sugar moieties; nucleotide mimetics, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids, and locked nucleic acids (LNAs), as well as combinations of two or more of any of the foregoing. In another embodiment, at least one or more nucleotides in the oligonucleotide comprises a non-natural modification to the nucleotide base.In another embodiment, the oligonucleotide is selected from any of the sequences in Table 2 (SEQ ID NOs: 14-50), or a portion thereof, alone or in combination, or from sequences having at least 70, 75, 80, 84, 85, 88, 92, 93, 94, 95, or 96% identity to the entire target sequence in the IL7R RNA. In another embodiment, the oligonucleotide targets any of the sequences in Table 2 (SEQ ID NOs: 14-50), or a portion thereof. In another embodiment, the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier. In another embodiment, the cancer shows a low response to conventional immunotherapy (e.g., hepatocellular carcinoma). In another embodiment, the method further comprises combination therapy of the SM-ASO with one or more active agents effective in the treatment of cancer, such as, but not limited to, an immune checkpoint inhibitor (e.g., nivolumab), a therapeutic antibody (e.g., herceptin), a conventional chemotherapeutic agent (e.g., taxol), or radiation therapy. In another aspect, the method further comprises obtaining cells from the patient and modifying the cells to transiently or permanently express an oligonucleotide that specifically binds to a sequence in interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6. In another aspect, the method further comprises generating a vector expressing an oligonucleotide that specifically binds to a sequence in interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6 for use in gene therapy and treating the patient with the vector.

[0020] In another embodiment, the invention includes a composition comprising an oligonucleotide that is an antisense oligonucleotide (ASO) or splice modifier antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in the pre-mRNA of the interleukin 7 receptor (IL7R) that affects the splicing of exon 6, where the SM-ASO reduces the inclusion of exon 6 in the IL7R pre-mRNA and increases the expression of the soluble isoform of IL7R (sIL7R). In another aspect, the oligonucleotide in the composition specifically binds to a sequence in the IL7R pre-mRNA at at least one of the group consisting of an exonic splice enhancer sequence (ESE) and / or an intronic splice enhancer sequence (ISE), thereby reducing the inclusion of exon 6 and increasing the expression of sIL7R. In another aspect, the oligonucleotide in the composition specifically binds to a sequence on the IL7R pre-mRNA at an intron-exon splice site, a branch point sequence, and / or a polypyrimidine tract.In another embodiment, at least one or more nucleotides in the oligonucleotide contain a non-natural modification, including a modification or substitution of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, selected from the following: one or more phosphorothioates, dithiophosphates, phosphodiesters, methylphosphonates, phosphoramidates, methylphosphonates, phosphotriesters, phosphoroaridates, morpholinos, amidate carbamates, carbamate), carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbone, locked nucleic acid backbone, peptide backbone, phosphotriester backbone, phosphoramidate backbone, siloxane backbone, carboxymethyl ester backbone, acetamidate backbone, carbamate backbone, thioether backbone, bridged methylene phosphonate backbone, phosphorothioate backbone, methyl phosphonate backbone, alkyl phosphonate backbone, phosphate ester backbone, methyl phosphorothioate backbone, alkyl phosphonothioate backbone, phosphorothioate backbone, Partially or fully modified backbones such as dithioate backbones, carbonate backbones, phosphate triester backbones, carboxymethyl ester backbones, methyl phosphorothioate backbones, phosphorodithioate backbones, backbones with p-ethoxy linkages; sugar modifications such as 2'-O-methyl (2'-O-methyl nucleotides), 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties, or bicyclic sugar moieties; nucleotide mimetics, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids, and locked nucleic acids (LNAs), as well as any combination of two or more of any of the foregoing. In another embodiment, at least one or more nucleotides in the oligonucleotide comprises a non-natural modification to the nucleotide base.In another embodiment, the oligonucleotide is selected from any of the sequences in Table 2 (SEQ ID NOs: 14-50), or portions thereof, alone or in combination, or from sequences having at least 70, 75, 80, 84, 85, 88, 92, 93, 94, 95, or 96% identity to the entire target sequence within the IL7R RNA. In another embodiment, the oligonucleotide targets, in whole or in part, any of the sequences in Table 2 (SEQ ID NOs: 14-50). In another embodiment, the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier. In another embodiment, the composition is suitable for administration for the treatment of cancer.

[0021] In yet another embodiment, the invention includes a method of reducing inclusion of exon 6 in interleukin 7 receptor (IL7R) pre-mRNA, the method comprising contacting with a splice modulating antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6, the SM-ASO reducing inclusion of exon 6 in IL7R pre-mRNA and increasing expression of a soluble isoform of IL7R (sIL7R). In another aspect, the oligonucleotide in the composition specifically binds to a sequence in IL7R pre-mRNA in at least one of the group consisting of an exonic splice promoting sequence (ESE) and / or an intronic splice promoting sequence (ISE), thereby reducing inclusion of exon 6 and increasing expression of sIL7R. In another aspect, the SM-ASO in the composition specifically binds to a sequence on IL7R pre-mRNA at an intron-exon splice site, a branch point sequence, and / or a polypyrimidine tract.In another embodiment, at least one or more nucleotides in the SM-ASO contain a non-natural modification, including a modification or substitution of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, selected from the following: one or more phosphorothioates, dithiophosphates, phosphodiesters, methylphosphonates, phosphoramidates, methylphosphonates, phosphotriesters, phosphoroaridates, morpholinos, amidate carbamates, carbamate), carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbone, locked nucleic acid backbone, peptide backbone, phosphotriester backbone, phosphoramidate backbone, siloxane backbone, carboxymethyl ester backbone, acetamidate backbone, carbamate backbone, thioether backbone, bridged methylene phosphonate backbone, phosphorothioate backbone, methyl phosphonate backbone, alkyl phosphonate backbone, phosphate ester backbone, methyl phosphorothioate backbone, alkyl phosphonothioate backbone, phosphorothioate backbone, Partially or fully modified backbones such as dithioate backbones, carbonate backbones, phosphate triester backbones, carboxymethyl ester backbones, methyl phosphorothioate backbones, phosphorodithioate backbones, backbones with p-ethoxy linkages; sugar modifications such as 2'-O-methyl (2'-O-methyl nucleotides), 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties, or bicyclic sugar moieties; nucleotide mimetics, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids, and locked nucleic acids (LNAs), as well as any combination of two or more of any of the foregoing. In another embodiment, at least one or more nucleotides in the SM-ASO contain non-natural modifications to the nucleotide base. In another embodiment, the SM-ASO increases the stability of an IL7R mRNA lacking exon 6 by targeting the IL7R exon 5 to exon 7 boundary. In another embodiment, the SM-ASO enhances translation of an IL7R mRNA lacking exon 6.In another embodiment, the SM-ASO is selected from any of the sequences in Table 2, or a portion thereof, alone or in combination, or from sequences having at least 70, 75, 80, 84, 85, 88, 92, 93, 94, 95, or 96% identity to the entire target sequence in the IL7R RNA. In another embodiment, the oligonucleotide targets any of the sequences in Table 2, in whole or in part. In another embodiment, the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier. In another embodiment, the disorder is a type of cancer. In another embodiment, the method further comprises obtaining cells from the patient and modifying the cells to express, either transiently or permanently, an oligonucleotide that specifically binds to a sequence of the interleukin 7 receptor (IL7R) pre-mRNA that affects exon 6 splicing. In another embodiment, the method further comprises generating a vector expressing an oligonucleotide that specifically binds to a sequence of the interleukin 7 receptor (IL7R) pre-mRNA that affects exon 6 splicing for use in gene therapy, and treating the patient with the vector.

[0022] In another embodiment, the invention includes a composition for increasing inclusion of exon 6 in interleukin 7 receptor (IL7R) pre-mRNA, the method comprising contacting with a splice-modifying antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6, where the SM-ASO reduces inclusion of exon 6 in IL7R pre-mRNA and increases expression of a soluble isoform of IL7R (sIL7R). In one aspect, the composition further comprises combination therapy of the SM-ASO with one or more active agents effective in the treatment of cancer, such as, but not limited to, an immune checkpoint inhibitor (e.g., nivolumab), a therapeutic antibody (e.g., herceptin), a conventional chemotherapeutic agent (e.g., taxol), or radiation therapy.

[0023] In another embodiment, the invention comprises a vector expressing a nucleic acid comprising an oligonucleotide that is an antisense oligonucleotide (ASO) or a splice-modifying antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in the interleukin-7 receptor (IL7R) pre-mRNA that affects the splicing of exon 6, where the SM-ASO reduces the inclusion of exon 6 in the IL7R pre-mRNA and increases expression of the soluble isoform of IL7R (sIL7R). In one aspect, the vector is a viral vector or a plasmid. For a more complete understanding of the features and advantages of the present invention, reference should now be made to the following detailed description of the invention along with the accompanying drawings. [Brief description of the drawings]

[0024] [Figure 1A] Figures 1A-1C show validation of the GFP-IL7R fluorescent splicing reporter for screening of splice-regulatory antisense oligonucleotides (SM-ASOs). [Figure 1B] Same as above. [Figure 1C] Same as above. [Figure 2A] 2A-2E show targeted screening of IL7R splice regulation antisense oligonucleotides (SM-ASOs) complementary to sequences in exon 6. [Figure 2B] Same as above. [Figure 2C] Same as above. [Figure 2D] Same as above. [Figure 2E] Same as above. [Figure 3A] 3A-3E show SM-ASO walk screen targeting sequences in IL7R introns 5 and 6. [Figure 3B] Same as above. [Figure 3C] Same as above. [Figure 3D] Same as above. [Figure 3E] Same as above. [Figure 4A]Figures 4A-4D show the effect of select SM-ASOs on the expression of IL7R protein isoforms. [Figure 4B] Same as above. [Figure 4C] Same as above. [Figure 4D] Same as above. [Figure 5A] Figures 5A-5D show the dose-response effect of lead SM-ASO reducing sIL7R upon modulation of IL7R exon 6 splicing. [Figure 5B] Same as above. [Figure 5C] Same as above. [Figure 5D] Same as above. [Figure 6A] Figures 6A-6D show the dose-response effect of lead SM-ASO increasing sIL7R upon modulation of IL7R exon 6 splicing. [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 6D] Same as above. [Figure 7A] 7A-7B show correction by IL7R-005 of the effects of a genetic abnormality that increases IL7R exon 6 exclusion and increases sIL7R levels in MS. [Figure 7B] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] While the making and using of various embodiments of the invention are discussed in detail below, it should be understood that the invention provides many applicable inventive concepts that can be implemented in a wide variety of specific contexts. The specific embodiments discussed herein are merely specific examples of how to make and use the invention and do not limit the scope of the invention.

[0026] To facilitate understanding of the present invention, a number of terms are defined below. Terms defined herein have meanings commonly understood by those of ordinary skill in the art in the areas relevant to the present invention. Terms such as "a", "an", and "the" are not intended to refer to only one entity, but include general classes of which specific examples can be used for illustration. While the terms herein are used to describe specific embodiments of the present invention, their usage does not limit the present invention, except as outlined in the claims.

[0027] The present invention relates to novel compositions and methods for decreasing or increasing soluble IL7R (sIL7R) to treat autoimmune diseases (e.g., multiple sclerosis) or cancer, respectively. The present invention uses SM-ASO to control alternative splicing of interleukin-7 receptor (IL7R) pre-mRNA to prevent or decrease expression of sIL7R, or conversely, increase expression of sIL7R. For example, in view of the ability of sIL7R to increase autoreactivity, it is demonstrated herein that increasing sIL7R levels enhances response to currently used immunotherapies (e.g., immune checkpoint inhibitors).

[0028] Unless otherwise specified, all technical and scientific terms used herein generally have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. Generally, the nomenclature and laboratory procedures in cell culture, molecular genetics, organic chemistry, organic synthesis, nucleic acid chemistry and nucleic acid hybridization used herein are those known and commonly used in the art. In addition, standard techniques can be used for nucleic acid and peptide synthesis. Such techniques and procedures are generally carried out according to conventional methods known in the art and derived from various general references (e.g., Sambrook and Russell, 2012, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Press, Cold Spring Harbor, NY, and Ausubel et al., 2012, Current Protocols in Molecular Biology, John Wiley & Sons, NY; the relevant portions are incorporated herein by reference).

[0029] Conventional notation is used herein to describe polynucleotide sequences, e.g., for sequences such as those that will be coding sequences, the left end of a single-stranded polynucleotide sequence is the 5'-end and the opposite end is the 3'-end (right-hand end); the left end of a double-stranded polynucleotide sequence is referred to as the 5'-direction and the opposite end is referred to as the 3'-direction (right-hand direction). The direction of 5' to 3' addition of nucleotides to a nascent RNA transcript is referred to as the transcription direction. The DNA strand that has the same sequence as the mRNA is referred to as the "coding strand." A sequence on a DNA or RNA strand that is 5' to a reference point on the DNA or RNA is referred to as the "upstream sequence" and a sequence on a DNA or RNA strand that is 3' to a reference point on the DNA or RNA is referred to as the "downstream sequence."

[0030] As used herein, the term "antisense" refers to an oligonucleotide having a sequence that hybridizes to a target sequence in an RNA by Watson-Crick base pairing to form an RNA:oligonucleotide heteroduplex with the target sequence, usually an mRNA or pre-mRNA. Antisense oligonucleotides may have exact sequence complementarity or close complementarity to the target sequence. These antisense oligonucleotides may block or inhibit translation of an mRNA, modulate processing of an mRNA to produce a splice variant of the mRNA, and / or promote specific degradation of a given mRNA or variant of an mRNA. One non-limiting example may also be RNase H-dependent degradation. It is not necessary that the antisense sequence be complementary only to the coding portion of an RNA molecule. The antisense sequence may be complementary to regulatory sequences identified on non-coding regions (e.g., introns, untranslated regions) of a protein-encoding RNA molecule, which control expression of the coding sequence. Antisense oligonucleotides are typically from about 5 to about 100 nucleotides in length, more typically from about 7 to about 50 nucleotides in length, and even more typically from about 10 to about 30 nucleotides in length.

[0031] As used herein, the term "nucleic acid" or "nucleic acid molecule" refers to any DNA or RNA molecule, whether single-stranded or double-stranded, regardless of linear or circular form. With respect to the nucleic acid of the present invention, the term "isolated nucleic acid", when applied to DNA or RNA, refers to a DNA or RNA molecule that is separated from adjacent sequences in the natural genome or gene product of the organism from which it is derived. For example, "isolated nucleic acid" can include a DNA molecule that is inserted into a vector, such as a plasmid or viral vector, or that is integrated into the genomic DNA of a prokaryotic or eukaryotic cell or host organism.

[0032] As used herein, the term "specifically hybridize" or "substantially complementary" refers to the binding between two nucleotide molecules that are sufficiently complementary to allow hybridization under the given conditions commonly used in the art.Examples of low, medium or intermediate and high stringency hybridization conditions are well known to those skilled in the art, for example, with the aid of Sambrook and Russell, 2012, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Press, Cold Spring Harbor, NY, or Ausubel et al., 2012, Current Protocols in Molecular Biology, John Wiley & Sons, NY, the relevant parts of which are incorporated herein by reference.

[0033] As used herein, the phrase "chemically modified oligonucleotide" refers to short nucleic acids (DNA or RNA) that may be sense or antisense that contain modifications or substitutions such as those taught by Wan and Seth, "The Medicinal Chemistry of Therapeutic Oligonucleotides", J. Med. Chem. 2016, 59, 21, 9645-9667 (relevant portions of which are incorporated herein), which may include modifications of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, which is naturally composed of phosphates, as known in the art. Non-limiting examples of modified or nucleotide analogs include nucleotides having phosphate modifications including, but not limited to, one or more phosphorothioate, phosphorodithioate, phosphodiester, methylphosphonate, phosphoramidate, methylphosphonate, phosphotriester, phosphoroalidate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutions (see, e.g., Hunziker and Leumann (1995) Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods, VCH, 331-417; Mesmaeker et al.(1994)Novel Backbone Replacements for Oligonucleotides,in Carbohydrate Modifications in Antisense Research, ACS, 24-39); nucleotides having modified sugars (see, e.g., U.S. Patent Application Publication No. 2005 / 0118605) and sugar modifications such as 2'-O-methyl (2'-O-methyl nucleotides) and 2'-O-methyloxyethoxy (2'-O-MOE), 2'-O-alkyl modified sugar moieties, or bicyclic sugar moieties; and nucleotide mimetics such as, but not limited to, peptide nucleic acids (PNAs), morpholino nucleic acids, cyclohexenyl nucleic acids, anhydrohexitol nucleic acids, glycol nucleic acids, threose nucleic acids, and locked nucleic acids (LNAs), as well as fully modified sugar phosphate backbones, locked nucleic acid backbones, peptide backbones, phosphotriester backbones, phosphoramidate backbones, siloxane backbones, carboxymethyl ester backbones, acetamidate backbones, carbamate backbones, thioether backbones, bridged methylene phosphonate backbones, phosphorothioate backbones, methyl phosphonate backbones, alkyl phosphonate backbones, phosphatides ... Partially or fully modified backbones, such as phosphate ester backbones, alkyl phosphonothioate backbones, phosphorodithioate backbones, carbonate backbones, phosphate triester backbones, carboxymethyl ester backbones, methyl phosphorothioate backbones, phosphorodithioate backbones, backbones having p-ethoxy bonds; as well as any combination of two or more of any of the foregoing (e.g., U.S. Pat. Nos. 5,886,165; 6,140,482; 5,69 (See US Pat. Nos. 3,773; 5,856,462; 5,973,136; 5,929,226; 6,194,598; 6,172,209; 6,175,004; 6,166,197; 6,166,188; 6,160,152; 6,160,109; 6,153,737; 6,147,200; 6,146,829; 6,127,533; and 6,124,445).

[0034] As used herein, the term "expression cassette" refers to a nucleic acid molecule that contains a coding sequence operably linked to promoter / regulatory sequences necessary for the transcription, processing, and optionally, translation or splicing of the coding sequence.

[0035] IL7R SM-ASOs that reduce sIL7R can be used to treat diseases or disorders such as autoimmune and / or inflammatory diseases. IL7R SM-ASOs that increase sIL7R can be used for cancer immunotherapy applications. Whether increasing or decreasing the expression of sIL7R message or protein, the present invention can be used with gene therapy and ex vivo applications. For example, oligonucleotides can be used in methods where cells are isolated from the subject or another subject, the cells are modified to express an oligonucleotide that modulates the expression of sIL7R, and the cells can then be returned to the subject. The present invention can be used with various known delivery and expression methods, such as plasmids or viral vectors. The present invention can also be used with all cell modification methods, such as gene editing, delivery of nucleic acids (any natural, synthetic, or modified nucleic acid), proteins (full-length proteins or peptides), whether transiently or permanently, or under the control of a regulatable promoter. The oligonucleotides or vectors expressing them can be delivered via known methods, such as transfection, electroporation, carrier-mediated, viral, etc.

[0036] As used herein, the term "promoter / regulatory sequence" refers to a nucleic acid sequence required for expression of a gene product operably linked to the promoter / regulatory sequence. In some cases, the promoter / regulatory sequence may be a core promoter sequence, while in other cases, the sequence may also include an enhancer sequence and other regulatory elements required for expression of the gene product. The promoter / regulatory sequence may be, for example, a sequence that promotes expression of a gene product constitutively and / or inducibly. As used herein, the term "inducible promoter" refers to a nucleotide sequence that, when operably linked to a polynucleotide that encodes or specifies a gene product, causes the gene product to be produced substantially only in the presence of an inducer corresponding to the promoter.

[0037] As used herein, the terms "percent similarity," "percent identity," and "percent homology," when referring to a comparison between two particular sequences, specify the percentage or bases along a particular sequence that are the same. Percentages of similarity, identity, or homology can be calculated, for example, using the University of Wisconsin GCG software program or equivalent.

[0038] As used herein, the term "replicon" refers to any genetic element, e.g., a plasmid, cosmid, bacmid, phage, or virus, that is capable of replicating primarily under its own control. A replicon may be RNA or DNA, and may be single- or double-stranded.

[0039] As used herein, the term "vector" refers to a genetic element, such as a plasmid, cosmid, bacmid, phage or virus, to which another genetic sequence or element (DNA or RNA) can be attached. A vector can be a replicon, which effects the replication of the attached sequence or element. An "expression vector" is a vector that facilitates the expression of a nucleic acid, such as an oligonucleotide, or a nucleic acid sequence encoding a polypeptide, in a host cell or organism.

[0040] As used herein, the term "operably linked" refers to a nucleic acid sequence that is placed in a functional relationship with another nucleic acid sequence. Examples of nucleic acid sequences that can be operably linked include, but are not limited to, promoters, transcription terminators, transcription enhancers or activators, and heterologous genes that, when transcribed and, if necessary, translated, produce a functional product, such as a protein, a ribozyme, or an RNA molecule.

[0041] As used herein, the term "oligonucleotide" refers to a single- or double-stranded nucleic acid strand that is usually shorter than the coding sequence of a gene, e.g., an oligonucleotide is usually at least 4-6 and up to about 200 bases or base pairs long, with the most typical oligonucleotides being 8-20, 10-25, 12-30, or about 30, 35, 40, or 50 bases or base pairs long. In a specific example of the present invention, an oligonucleotide is a nucleic acid strand having a sequence that regulates the inclusion of exon 6 in the pre-mRNA of the interleukin 7 receptor (IL7R) gene, and is defined as a nucleic acid molecule consisting of two or more, preferably five or more, ribo- or deoxyribonucleotides. The exact size of the oligonucleotide will depend on various factors and on the specific application and use of the oligonucleotide, and may vary as would be known to one of skill in the art without undue experimentation following the teachings herein and as taught, for example, in Sambrook and Russell, 2012, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Press, Cold Spring Harbor, NY, or Ausubel et al., 2012, Current Protocols in Molecular Biology, John Wiley & Sons, NY, the relevant portions of which are incorporated herein by reference.

[0042] As used herein, the term "splice variant or isoform of mRNA" refers to a variant mRNA, which may be defective or pathogenic and may be the result of alternative splicing of a protein-coding RNA. A splicing event that produces a splice variant of an mRNA that is defective or results in a pathological condition is referred to as a splicing defect in the present invention. One example of such a splicing defect is the exclusion of exon 6 of IL7R, which leads to the expression of a shorter protein, soluble IL7R (sIL7R). sIL7R is secreted from cells, resulting in its presence, for example, in the bloodstream or body fluids. The present invention targets elements (i.e., sequences) in IL7R pre-mRNA that control the inclusion or exclusion of IL7R exon 6 in the final mature or processed mRNA, or sequences in sIL7R mRNA that control its translation or stability.

[0043] As used herein, the term "splice variant or isoform of a protein" refers to a variant protein, which may be defective or pathogenic and may be the result of alternative splicing of the RNA encoding the protein. Alternatively, when discussing variants that increase degradation, these splice variants will reduce or eliminate protein production. Splicing events that produce splice variants of proteins that are defective or result in pathology are referred to as splicing defects in the present invention. One example of such splicing defects is the exclusion of exon 6 of IL7R, which leads to the expression of a shorter protein, soluble IL7R (sIL7R). sIL7R is secreted from cells, resulting in its presence in, for example, the bloodstream or body fluids. The present invention targets elements (i.e., sequences) within IL7R pre-mRNA that control the inclusion or exclusion of IL7R exon 6 in the final mature or processed mRNA, or sequences within sIL7R mRNA that control its translation or stability.

[0044] As used herein, the term "treatment" means to reverse, alleviate, delay, inhibit progression, and / or prevent the onset of a disease or disorder or one or more symptoms thereof, as applied to a pathology or onset in a subject, for example, an autoimmune disease or disorder. In some embodiments, treatment may be applied after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered prior to symptoms (e.g., taking into account the course of symptoms and / or one or more other susceptibility factors) or after symptoms have resolved, for example, to prevent or delay their recurrence. One such non-limiting example is relapsing-remitting MS.

[0045] As used herein, the terms "effective amount" and "pharmaceutical effective amount" refer to a sufficient amount of an agent to obtain a desired biological result. Preferably, a sufficient amount of an agent does not induce toxic side effects. The present invention using IL7R SM-ASO to reduce sIL7R should result in a reduction or alleviation of signs, symptoms, or causes of an autoimmune disease or disorder. By design, the present invention is not expected to cause a decrease in the host's immune response, and therefore has few or few side effects associated with widespread immunosuppression. The appropriate effective amount in any individual case can be determined by one of ordinary skill in the art using routine experimentation. The present invention using IL7R SM-ASO to increase sIL7R should result in a reduction or alleviation of signs, symptoms, or causes of cancer. By design, the present invention is expected to cause an enhancement of the host's immune response, and therefore is expected to enhance current immunotherapy. The appropriate effective amount in any individual case can be determined by one of ordinary skill in the art using routine experimentation.

[0046] The present invention may be provided with one or more "pharmaceutical acceptable" agents, carriers, buffers, salts, or other agents listed in the United States Pharmacopoeia or other generally recognized pharmacopoeias for use in animals and more specifically in humans, usually indicating approval by federal or state regulatory agencies.Exemplary pharmaceutical acceptable formulations for use with oligonucleotides include salts such as, but not limited to, calcium chloride dihydrate (United States Pharmacopoeia (USP)), magnesium chloride hexahydrate USP, potassium chloride USP, sodium chloride USP, and may further include buffers such as sodium phosphate dibasic anhydrous USP, sodium phosphate monobasic dihydrate USP, and water USP.Usually, the pH of the product may be altered to about pH 6.8, 6.9, 7.0, 7.1, or 7.2 using hydrochloric acid or sodium hydroxide.

[0047] The present invention may be provided in combination with one or more diagnostic tests used to demonstrate the effectiveness of the treatment.

[0048] As used herein, the term "carrier" refers to, for example, a diluent, preservative, solubilizer, emulsifier, adjuvant, excipient, auxiliary, or vehicle with which the active agent of the present invention is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or artificial origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water or saline and aqueous dextrose and glycerin solutions can be used as carriers. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences, 2012".

[0049] In one embodiment, the present invention relates to novel compositions and methods for treating autoimmune disorders, including but not limited to multiple sclerosis (MS). MS is the most common neurological disease of early adulthood, mediated by autoimmune mechanisms that cause demyelination and neuronal damage in the central nervous system, resulting in progressive neurological dysfunction. To date, there is no cure for the disease, and currently available treatments focus on preventing future immunological attacks, often by suppressing the immune system. This immunosuppressive approach causes numerous adverse side effects, among which are increased risks of cancer and serious, potentially fatal, infections. Thus, the inventors have developed a novel therapy that fulfills a clear unmet need for the development of an effective, well-tolerated therapy without adverse immunosuppressive side effects to prevent MS development.

[0050] The present invention also relates to novel compositions and methods for treating cancer. Cancer is the second leading cause of death in the United States and is mediated by many etiologies. To date, many cancers cannot be cured, but recently, therapies based on immune recognition and killing of cancer cells have brought new hope. Unfortunately, many patients undergoing immunotherapy do not respond adequately, and some cancer types (e.g., hepatocellular carcinoma) have low response rates. Therefore, the present inventors have developed novel therapeutic methods to meet the clear unmet need for the enhancement of conventional immunotherapy.

[0051] The present inventors have developed targeted antisense oligonucleotides, such as antisense oligonucleotides (ASOs) and / or splice-modulating antisense oligonucleotides (SM-ASOs), to correct specific MS pathogenesis. SM-ASOs have been demonstrated to be a novel and useful therapeutic approach for treating disorders caused by abnormal RNA splicing. Two such SM-ASOs have recently been approved by the FDA for the treatment of spinal muscular atrophy (Spinraza, Biogen) and Duchenne muscular dystrophy (Exondys 51, Sarepta Therapeutics).

[0052] Novel targeted therapeutic agents correct aberrant splicing of interleukin-7 receptor (IL7R) RNA, and elimination of alternative exon 6 results in high levels of pathogenic soluble IL7R (sIL7R). Several lines of evidence directly link and strongly support a role for alternative splicing of IL7R exon 6 in the pathogenesis of MS and other autoimmune diseases: (1) genetic variants increasing the exclusion of this exon are strongly associated with increased MS risk (Galarza-Munoz et al., 2017; Gregory et al., 2007); (2) sIL7R exacerbates disease severity and progression in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS (Lundstrom et al., 2013); and (3) sIL7R is elevated in patients with several autoimmune diseases, including MS, type I diabetes, rheumatoid arthritis, and systemic lupus erythematosus (Badot et al., 2011; Badot et al., 2013; Lauwerys et al., 2014; McKay et al., 2008; Monti et al., 2013).

[0053] The present inventors have developed several SM-ASOs (Table 1), including lead ASOs IL7R-005 and IL7R-006, which promote the inclusion of exon 6 in IL7R pre-mRNA and correct the expression of IL7R protein isoforms in cultured cells. Of critical importance to this therapeutic approach, these SM-ASOs reduce sIL7R levels without adversely affecting the expression of membrane-bound IL7R (mIL7R). To treat autoimmunity, the present invention is used to block specific sequences that promote the exclusion of exon 6 in IL7R pre-mRNA, thereby promoting the inclusion of exon 6 and reducing sIL7R levels. Furthermore, to treat cancer, the present invention is used to block specific sequences that promote the inclusion of exon 6 in IL7R pre-mRNA, thereby reducing the inclusion of exon 6 and increasing sIL7R levels. Those skilled in the art will appreciate that the SM-ASOs of the present invention can be used alone or in combination with other therapies. Furthermore, by simple single base mutations, SM-ASOs can be adapted to control splicing of exon 6 in allelic variants of human IL7R, or of IL7R in different animals, or in individuals with polymorphisms or mutations in the targeted sequence, thereby allowing the complementarity of the SM-ASO to the variant sequence to be tailored. [Table 1]

[0054] A wide variety of SM-ASOs can be used in the present invention, including those that include base or backbone modifications to the wide variety of SM-ASOs. Non-limiting examples of SM-ASOs can include naturally occurring nucleic acids, but can also include backbone or base modifications (chemically modified oligonucleotides) that increase the binding efficiency of the SM-ASO, increase the stability (e.g., half-life) of the SM-ASO, increase its expression, control its expression, distribution or localization, etc.

[0055] Current treatments for autoimmune diseases such as MS have helped autoimmune disease patients manage their symptoms, but these drugs are far from ideal, considering the various adverse side effects they cause, which can be severe and even fatal. The development of effective and safer MS drugs has been hindered by the complex nature of the disease, with multiple causes leading to MS pathogenesis. Given that all these etiologies result in a breakdown of immune tolerance to myelin, the field has focused so far on developing therapies that attenuate the immune response through various mechanisms. For example, natalizumab is designed to block the movement of leukocytes across the blood-brain barrier and their recruitment to sites of inflammation. Another example is ocrelizumab, which depletes B cells. However, both of these mechanisms (albeit through different actions) ultimately result in immune suppression. In order to provide patients with effective yet safer drugs, it is essential to develop novel therapies that target the correction of specific MS pathogenesis rather than addressing the consequences of a given pathogenesis through immune modulation (which we refer to herein as immune correction).

[0056] The canonical membrane-bound interleukin 7 receptor (mIL7R) has been a previous candidate for therapeutic intervention in MS and numerous autoimmune disorders. However, mIL7R is important for T cell homeostasis and normal immune function, and loss of IL7R function in both humans and mice causes significant immune deficiency (Maraskovsky et al., 1996; Peschon et al., 1994; Puel et al., 1998; Roifman et al., 2000). Thus, novel MS therapies that suppress mIL7R expression and function would result in significant immune deficiency. The therapeutic SM-ASOs developed herein correct the aberrant splicing of IL7R exon 6, and by doing so, they progressively reduce sIL7R levels while simultaneously preventing adverse effects on mIL7R expression and / or function. Thus, unlike current MS therapeutics that rely on immunosuppressive mechanisms, the therapeutic SM-ASOs of the present invention that reduce sIL7R (Table 1) are an option for effective and safer MS treatment that avoids immunosuppression. The SM-ASOs of the invention that reduce sIL7R (Table 1) represent a significant improvement over current drugs in that they correct the root of the problem rather than addressing the consequences by suppressing the immune system.

[0057] Furthermore, elevated levels of sIL7R (compared to normal levels of sIL7R in subjects without autoimmune disease) have been associated with other autoimmune diseases, such as type I diabetes, rheumatoid arthritis, and systemic lupus erythematosus, and patients with these diseases have been shown to have elevated levels of circulating sIL7R (Badot et al., 2011; Badot et al., 2013; Lauwerys et al., 2014; Monti et al., 2013). Thus, therapeutic SM-ASOs may be used to treat a number of diseases or disorders with elevated levels of sIL7R.

[0058] Cancer is the second leading cause of death in the United States. Given the many etiologies that contribute to cancer, effective treatments for many cancers are lacking. Cancer immunotherapy is a rapidly expanding field that uses the body's immune system as a novel treatment for previously difficult-to-control cancers. Immune checkpoint inhibitors such as monoclonal antibodies targeting the negative immune regulators CTLA-4 (Yervoy, Bristol-Myers Squibb) and PD-1 (pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been FDA approved. One example of their potential is a study in patients with previously untreated, inoperable or metastatic melanoma treated with a combination of nivolumab and ipilimumab, where an overall response rate of 50% was reported (Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, et al. 2015. N Engl J Med 373:23-34).

[0059] Recent cancer immunotherapies have brought new hope, but unfortunately, many patients receiving immunotherapy do not respond adequately, and some cancer types (e.g., hepatocellular carcinoma) have low response rates. For example, nivolumab has been FDA approved for patients with hepatocellular carcinoma who have not responded to the kinase inhibitor sorafenib, but the overall response rate among 154 patients tested was only 14.3%, and complete responses were observed in only three patients (NCT01658878). Although promising, these data indicate a critical need to increase response rates.

[0060] The need to increase immunotherapy response rates has motivated an intensive search for markers (e.g., PD-L1 expression and high microsatellite instability in tumor cells) that predict the success of currently employed immune checkpoint blockade. Less developed, but equally exciting, is the study of pro-immune modulators that may synergize with checkpoint blockade. High levels of sIL7R are thought to enhance immune responses by enhancing the bioavailability and / or bioactivity of the cytokine IL7, enhancing T cell survival (Lundstrom et al., 2013). This results in a pro-inflammatory environment that has the potential to enhance immune responses against cancer. Thus, the present invention uses SM-ASOs that enhance sIL7R, such as lead SM-ASOs IL7R-001 and IL7R-004, and additional SM-ASOs in Table 2, as novel immunotherapies for cancer. [Table 2] TIFF0007576835000003.tif107162

[0061] Figures 1A-1C show the validation of the GFP-IL7R fluorescent splicing reporter for screening of splice-modulating antisense oligonucleotides (SM-ASOs). Figure 1A shows a schematic diagram of the GFP-IL7R reporter showing the location of the SM-ASO target (red) and the corresponding cis-splicing element (blue). Figure 1B shows the Splicing analysis of IL7R exon 6 in transcripts from the GFP-IL7R reporter Figure 1C shows the results of the analysis of exon 6 splicing in IL7R-IL7R-derived GFP-IL7R cells. HeLa cells stably expressing WT (C) or mutant versions of the reporter (5'Mut, 5'Cons, ΔESE2 and ΔESS2) were transfected with control (Ctrl) or experimental (IL7R-001 and IL7R-002) SM-ASOs. Exon 6 splicing was analyzed by RT-PCR using primers specific for the GFP-IL7R reporter (+E6=exon 6 inclusion; -E6=exon 6 exclusion), and exon 6 inclusion percentage was calculated by the formula: [inclusion / (inclusion + exclusion)]*100. Figure 1C shows the results of the analysis of exon 6 splicing in IL7R-derived GFP-IL7R-derived GFP-IL7R-derived SM-ASOs. GFP expressionAnalysis of GFP mean fluorescence intensity (MFI) was quantified by flow cytometry. Data are shown normalized to control SM-ASO (Ctrl).

[0062] To evaluate the feasibility of this reporter system to screen for SM-ASOs that modulate the splicing of IL7R exon 6, we compared the effect of blocking a specific cis-acting splicing element in exon 6 with the mutation of the corresponding element. For example, SM-ASO IL7R-001 blocks the 5'-splice site of exon 6, pushing for a near-complete elimination of the exon equivalent to a mutation that abolishes the function of this 5'-splice site. Similarly, blocking the previously identified intra-exonic splicing enhancer 2 (ESE2) with IL7R-002 produces an equivalent effect to a mutation of this enhancer (ΔESE2). IL7R-002 has a lower affinity for IL7R RNA, which likely explains its slightly lower magnitude compared to ΔESE2. The fact that SM-ASO-mediated blocking or mutation of a given cis-splicing element produced an equivalent effect indicates the ability of SM-ASOs to control splicing decisions in this reporter system. More importantly, the observed changes in exon 6 splicing lead to the predicted changes in GFP expression, thereby validating the use of GFP expression as a readout of splicing outcomes in this reporter system.

[0063] Figures 2A-2E show the targeted screening of IL7R SM-ASOs complementary to cis-acting splicing elements within exon 6. Figure 2A shows a schematic of the GFP-IL7R splicing fluorescent reporter used in the screen. The genomic sequence of IL7R spanning introns 5 and 6 was cloned interrupted by the GFP coding sequence, such that GFP expression is determined by splicing of IL7R exon 6. Figures 2B and 2C show the analysis of GFP expression. HeLa cells stably expressing the fluorescent reporter were transfected with control (ASO-Ctrl) or experimental morpholino SM-ASOs (IL7R-001-IL7R-005) and GFP expression was quantified by flow cytometry. Figure 2B shows a representative histogram of GFP mean fluorescence intensity (MFI) for selected SM-ASOs and Figure 2C shows the quantification of GFP MFI normalized to control ASO (ASO-ctrl). The red dashed line indicates a validity cutoff of 1.5 fold change in GFP expression in either direction. Figure 2D shows splicing analysis of IL7R exon 6 in transcripts from the GFP-IL7R reporter. Splicing of IL7R exon 6 was analyzed in transcripts from the reporter by RT-PCR using primers specific for the GFP-IL7R reporter (+E6=exon 6 inclusion; -E6=exon 6 exclusion), and exon 6 inclusion percentage was determined by the formula: [inclusion / (inclusion+exclusion)]*100. The red dashed line indicates a validity cutoff of 1.5 fold change in exon 6 inclusion percentage. Figure 2E shows splicing analysis of IL7R exon 6 in transcripts from the endogenous IL7R gene. Splicing of IL7R exon 6 was analyzed in transcripts from the endogenous IL7R gene using primers specific for the endogenous transcript (FL=included exon 6; ΔE6=excluded exon 6) and exon 6 inclusion percentage was determined by the formula: [FL / (FL+ΔE6)]*100. For all panels, statistical significance was assessed by two-tailed Student's t-test comparing experimental ASOs versus controls (*p<0.05, **p<0.005, ***p<0.0005).

[0064] This targeted screening revealed several SM-ASOs that modulate splicing in either direction of IL7R exon 6. For example, blocking the 5' splice site (IL7R-001) or the previously identified ESE2 (IL7R-002) induces almost complete exon exclusion. Most importantly, it revealed IL7R-005, which blocks intra-exonic splicing suppressor element 3 (ESS3), which promotes almost complete exon inclusion. This one SM-ASO turned out to be particularly useful for the treatment of autoimmune diseases. In addition, we revealed four SM-ASOs (IL7R-001, IL7R-002, IL7R-003 and IL7R-004) that enhance exon 6 exclusion. These are candidates for cancer immunotherapy applications. Importantly for therapeutic purposes, all tested SM-ASOs induced similar modulation of exon 6 splicing in transcripts from both the GFP-IL7R reporter and the endogenous IL7R gene.

[0065] Figures 3A-3E show SM-ASO walk screen targeting sequences in IL7R introns 5 and 6. Figure 3A shows a schematic of the SM-ASO walk approach. As an example, we designed morpholino SM-ASOs of 15-25 nt length complementary to overlapping sequences every 5 nt within the intronic regions proximal to IL7R exon 6. These regions include the last 209 nt of IL7R intron 5, avoiding the last 40 nt containing core splicing elements such as branch point sequences, polypyrimidine tracts and 3'-splice sites, and the first 169 nt of IL7R intron 6, avoiding the first 15 nt containing the 5'-splice site. Control (ASO-Ctrl) or experimental SM-ASOs targeting these intronic regions (e.g., IL7R-006-IL7R-065) were transfected into HeLa cells stably expressing a reporter system as shown in Figure 2A. IL7R-001 and IL7R-005 were used as positive controls. Figures 3B and 3C show GFP expression analysis of SM-ASOs targeting introns 5 (Figure 3B) and 6 (Figure 3C). GFP mean fluorescence intensity (MFI) was measured by flow cytometry as previously shown. Red and blue lines indicate the cutoff for a 20% increase or decrease in GFP MFI, respectively. Figures 3D and 3E show splicing analysis of IL7R exon 6 in transcripts from GFP-IL7R reporters for selected SM-ASOs targeting introns 5 (Figure 3D) and 6 (Figure 3E). The percentage of exon 6 inclusion in transcripts from the reporters was determined as previously described. The red dashed line indicates the level of exon 6 inclusion in the control (ASO-Ctrl). For all panels, statistical significance was assessed by two-tailed Student's t-test comparing experimental SM-ASO versus control (*p<0.05, **p<0.005, ***p<0.0005). This approach revealed another SM-ASO, IL7R-006, which promotes high levels of exon 6 inclusion by blocking a sequence within intron 6. Within the target sequence of SM-ASO IL7R-006 (UAAUAAAGAGGGUGAUUGUG), there is a polyadenylation signal (AAUAAA) near the 5' splice site of intron 6, which we previously found to promote exon 6 skipping, presumably by blocking the 5'-splice site when bound by CPSF1 (Evsyukova et al., 2013). However, our IL7R-006 oligonucleotide blocks a 20 nt sequence that contains an additional splicing regulatory sequence, which differs from the results reported in Evsyukova et al., 2013.

[0066] In addition to IL7R-006, we also uncovered additional target sequences that increase exon 6 inclusion (listed in Table 1). These include two clusters of SM-ASOs, cluster 1 (intron 5) and cluster 2 (intron 6), and several other SM-ASOs that increase exon 6 inclusion, albeit less efficiently than the lead SM-ASOs IL7R-005 and IL7R-006. We are currently refining the final target sequences for the newly discovered SM-ASOs to improve their efficiency.

[0067] This screen also revealed several SM-ASOs that reduced exon 6 inclusion (as seen as increased GFP expression in Figures 3B and 3C, and as listed in Table 2). The latter are candidates for therapeutic intervention in cancer immunotherapy. Importantly, this approach identified novel SM-ASO targets for autoimmunity and cancer to be tested in preclinical models.

[0068] Figures 4A-4D show the effect of selected SM-ASOs on expression of IL7R protein isoforms. HeLa cells were transfected with control (ASO-Ctrl) or experimental (IL7R-001, IL7R-004, IL7R-005 and IL7R-006) morpholino SM-ASOs using the Endo-Porter gene transfection system (Gene Tools) as previously described. Figure 4A shows splicing analysis of exon 6 in transcripts from the endogenous IL7R gene. Total RNA was isolated from cells and the percentage of exon 6 inclusion was determined by RT-PCR as previously described. Figure 4B shows quantification of soluble IL7R (sIL7R) secretion. Secretion of sIL7R was quantified by ELISA in supernatants collected from cells in panel A. Data are shown as the mean absorbance of experimental SM-ASOs normalized to control (ASO-Ctrl). Figure 4C shows quantification of cell surface expression of membrane-bound IL7R (mIL7R). Cell surface expression of mIL7R was determined by flow cytometry using IL7R staining in untreated cells. Data are shown as mean fluorescence intensity (MFI) of IL7R staining normalized to control. Figure 4D shows the ratio of IL7R protein isoform expression. The ratio of mIL7R to sIL7R (mIL7R / sIL7R) was determined by dividing the value of mIL7R cell surface expression (Figure 4C) by the value of sIL7R secretion (Figure 4B). In all panels, statistical significance was assessed by two-tailed Student's t-test comparing experimental SM-ASO vs. control (*p<0.05, **p<0.005, ***p<0.0005).

[0069] These results demonstrate that SM-ASO targeting sequences in IL7R exon 6 or intron 6 not only induces the desired outcome in exon 6 splicing, but more importantly, induces the desired outcome in a certain ratio of IL7R protein isoforms (mIL7R / sIL7R). Notably, IL7R-005 and IL7R-006 reduce sIL7R levels with minimal impact on mIL7R cell surface expression. The latter is crucial for the treatment of MS and autoimmunity, since suppression of mIL7R expression or activity leads to immunosuppression. SM-ASOs IL7R-005 and IL7R-006 meet the first efficacy endpoint, which restores IL7R protein isoforms. Importantly, these SM-ASOs are predicted to be safe and effective therapeutics for MS and other autoimmune diseases through a mechanism that prevents immunosuppression.

[0070] In addition, these analyses show that IL7R SM-ASOs that reduce exon 6 inclusion (IL7R-001 and IL7R-004) effectively increase sIL7R levels, fulfilling the first efficacy endpoint for a promising cancer immunotherapy. These SM-ASOs are predicted to enhance the immune system's ability to fight off and eradicate cancer cells.

[0071] Figures 5A-5D show dose-response modulation of IL7R exon 6 splicing of lead SM-ASOs reducing sIL7R. HeLa cells stably expressing a fluorescent reporter were transfected with control (ASO-Ctrl = 0 µM) or experimental (IL7R-005 and IL7R-006) morpholino SM-ASOs at increasing concentrations [0, 1, 5, and 10 µM] as previously described. Figures 5A and 5B show analysis of GFP expression. GFP mean fluorescence intensity (MFI) was measured by flow cytometry as previously described. Figure 5A shows a representative histogram of GFP MFI for different concentrations of IL7R-005, and Figure 5B shows normalized GFP MFI as a function of SM-ASO concentration. Figures 5C and 5D show splicing analysis of IL7R exon 6 in transcripts from the reporter (Figure 5C) or the endogenous gene (Figure 5D). The percentage of exon 6 inclusion in transcripts from reporter or endogenous genes was determined as described above and is shown as a function of SM-ASO concentration. For all panels, statistical significance was assessed by two-tailed Student's t-test comparing experimental concentrations versus control (*p<0.05, **p<0.005, ***p<0.0005).

[0072] Figures 6A-6D show dose-response modulation of IL7R exon 6 splicing of lead SM-ASOs increasing sIL7R. HeLa cells stably expressing a fluorescent reporter were transfected with control (ASO-Ctrl=0 μM) or experimental (IL7R-001 and IL7R-004) morpholino SM-ASOs at increasing concentrations [0, 1, 5, and 10 μM] as previously described. Figures 6A and 6B show analysis of GFP expression. GFP mean fluorescence intensity (MFI) was measured by flow cytometry as previously described. Figure 6A shows a representative histogram of GFP MFI for different concentrations of IL7R-001, and Figure 6B shows normalized GFP MFI as a function of SM-ASO concentration. Figures 6C and 6D show splicing analysis of IL7R exon 6 in transcripts from the reporter (Figure 6C) or the endogenous gene (Figure 6D). The percentage of exon 6 inclusion in transcripts from reporter or endogenous genes was determined as described above and is shown as a function of SM-ASO concentration. For all panels, statistical significance was assessed by two-tailed Student's t-test comparing experimental concentrations versus control (*p<0.05, **p<0.005, ***p<0.0005).

[0073] Analyses of Figures 5A-5D and 6A-6D show that IL7R exon 6 splicing can be fine-tuned in a dose-dependent manner by manipulating the dose of SM-ASO used, revealing a minimally effective concentration for IL7R splicing modulation in cell culture. Importantly, these results can be used to extrapolate in vivo dosing in preclinical studies in non-human primates and clinical trials in humans. This dose-response analysis provides an example of dose-responsiveness of a lead SM-ASO and does not limit our application to the range of concentrations tested.

[0074] Figures 7A-7B show correction by IL7R-005 of the aberrant exclusion of IL7R exon 6 driven by the MS-associated SNP rs6897932. HeLa cells stably expressing a version of the GFP-IL7R reporter containing either the protective "T" allele or the risk "C" allele of the MS-associated variant rs6897932 in IL7R exon 6 were transfected with either a control SM-ASO (ASO-Ctrl) or IL7R-005. Figure 7A shows splicing analysis of IL7R exon 6 in transcripts from the GFP-IL7R reporter containing alternative alleles (C or T) of rs68978932. The percentage of exon 6 inclusion was determined by RT-PCR as previously described. Figure 7B shows GFP expression analysis in the cells from Figure 7A. GFP mean fluorescence intensity (MFI) was measured by flow cytometry as described above and is shown normalized to cells expressing the "T" reporter treated with control SM-ASO. In all panels, statistical significance was assessed by two-tailed Student's t-test comparing experimental SM-ASO vs. control or as indicated (*p<0.05, **p<0.005, ***p<0.0005).

[0075] Previous studies by the present inventors and other researchers have found that the risk "C" allele of the genetic variant rs6897932 (C or T) in IL7R exon 6 increases MS risk by excluding exon 6 and increasing sIL7R levels (Gregory et al., 2007; Evsyukova et al., 2013; Hoe et al., 2010; Lundstrom et al., 2013). The above analysis showed that IL7R-005, a lead SM-ASO for the treatment of autoimmunity, restores the effect of the risk "C" allele of rs6897932, strongly supporting the therapeutic potential of IL7R-005.

[0076] Thus, the present inventors have described compositions and methods for using antisense oligonucleotides to control alternative splicing of exon 6 of interleukin 7 receptor (IL7R) RNA for therapeutic intervention in autoimmunity and cancer. These antisense oligonucleotides control the splicing of IL7R exon 6 by blocking specific signals embedded in IL7R RNA. These signals are specific sequences that determine the splicing outcome of IL7R exon 6. Furthermore, specific sequences in IL7R RNA to be blocked by antisense oligonucleotides to reduce sIL7R are listed in Table 1, including variants of these sequences, any part of these sequences, or any nucleotides adjacent to these sequences that increase the inclusion of IL7R exon 6 and thus reduce sIL7R secretion. Furthermore, additional signals in IL7R RNA to be blocked by antisense oligonucleotides to increase sIL7R are listed in Table 2, including variants of these sequences, any part of these sequences, or any nucleotides adjacent to these sequences that decrease the inclusion of IL7R exon 6 and thus increase sIL7R secretion. Blocking just a few nucleotides of these sequences can affect the splicing of exon 6, because the actual element driving the exclusion / inclusion is usually a 4-8 nt sequence within the targeting sequence, not the entire targeting sequence. For example, the critical sequence within the IL7R-005 targeting sequence is the last 5 nt UGGUC, and therefore an ASO that blocks only these 5 nt or a few nt of this sequence may be sufficient to produce the desired effect. However, to maximize targeting specificity and efficiency to functional sequences, oligonucleotides are often made to longer complementary sequences. Finally, it is well known that one or more bases in an antisense oligonucleotide can be substituted to alter base pairing and at the same time maintain high affinity, selectivity and efficient antisense activity to said target sequence.Non-limiting examples of SM-ASOs depending on their length are those having 15, 20, or 25 nucleotides, which may have 70, 75, 80, 84, 85, 87, 88, 90, 92, 93, 94, 95, or 96 percent identity to any of the sequences in Tables 1 and 2, or portions thereof, alone or in combination, in whole or in part, or to any biologically active permutations of these sequences, or sequences complementary thereto, for the treatment of autoimmune disease, inflammatory disease, or cancer, respectively, for use in compositions and methods for reducing expression of soluble IL7R by increasing inclusion of IL7R exon 6 for the treatment of autoimmune and / or inflammatory disease, or for increasing expression of soluble IL7R by decreasing inclusion of IL7R exon 6 for the treatment of cancer. In the case of SM-ASOs having 5, 10, 15, 20, or 25 nucleotides, the mismatches can be, for example, 1, 2, 3, 4, 5, or more mismatches. [Table 3]

[0077] It is contemplated that any embodiment discussed herein can be implemented with any method, kit, reagent, or composition of the invention, and vice versa. Further, the compositions of the invention can be used to practice the methods of the invention.

[0078] The specific embodiments described herein are offered by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific operations described herein. Such equivalents are considered to be within the scope of the invention and are covered by the claims.

[0079] All publications and patent applications mentioned in this specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0080] When used in conjunction with the term "comprising" in the claims and / or specification, the use of the word "a" or "an" may mean "one," but is also consistent with the meanings of "one or more," "at least one," and "one or more than one." The use of the term "or" in the claims is used in the sense of "and / or," unless expressly indicated to mean only alternatives or that the alternatives are mutually exclusive, but the present disclosure supports the definition to mean only alternatives and "and / or." Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of equipment error and the methods employed to measure that value, or that variation present in the test subjects.

[0081] As used herein, the words "comprising" (and any form of including, such as "comprise and comprises"), "having" (and any form of having, such as "have and has"), "including" (and any form of containing, such as "includes and include") or "containing" (and any form of including, such as "contains and contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. In some embodiments of any of the compositions and methods provided herein, "comprising" may be substituted with "consisting essentially of" or "consisting of." As used herein, the phrase "consisting essentially of" requires the specified integers or steps as well as those that do not materially affect the nature or function of the claimed invention. As used herein, the term "consisting" refers to the presence of only a stated integer (e.g., a feature, element, property, quality, method / process step, or limitation) or group of integers (a group of features, elements, properties, qualities, method / process steps, or limitations).

[0082] As used herein, the term "or combinations thereof" refers to all permutations and combinations of the listed items preceding the term. For example, "A, B, C, or combinations thereof" is intended to include at least one of A, B, C, AB, AC, BC, or ABC, and also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB, if order is important in the particular situation. Continuing with this example, expressly included are combinations including repeats of one or more items or terms, such as BB, AAA, AB, BBC, AAABCCCC, CBBAAA, CABABB, etc. One of ordinary skill in the art will understand that there is typically no limit to the number of items or terms in any combination, unless otherwise clear from the context.

[0083] As used herein, approximation words such as "without limitation," "about," "substantial," or "substantially," when so modified, refer to conditions that are not necessarily absolute or complete, but that may be considered close enough to warrant a person skilled in the art specifying the above conditions as existing. The extent to which the description may vary will depend on how large a change can be introduced and still allow a person skilled in the art to recognize that the modified characteristic still has the required unmodified properties and capabilities. Subject to the discussion in the preceding paragraph, generally, numerical values ​​herein modified by approximation words such as "about" may vary from the indicated value by at least ±1, 2, 3, 4, 5, 6, 7, 8, 10, 12, or 15%.

[0084] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. Although the compositions and methods of the present invention have been described in terms of preferred embodiments, changes may be made in the compositions and / or methods, and in the steps or sequence of steps of the methods described herein, without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

[0085] In order to assist the Patent Office and any readers of any patents issuing on this application in interpreting the claims appended hereto, applicants are advised that they do not intend to invoke 35 U.S.C. § 112, paragraph 6, or AIA 35 U.S.C. § 112, paragraph (f), or the equivalent, to any of the appended claims, as they existed as of the filing date of this case, unless the words "means for" or "step for" are expressly used.

[0086] For each claim, each dependent claim may depend both from the independent claim and from each preceding dependent claim for each and every claim, provided that the preceding claims provide appropriate antecedent references to claim terms or elements.

[0087] References Allcock, RJ, Williams, JH, and Price, P. (2001). The central MHC gene, BAT1, may encode a protein that down-regulates cytokine production. Genes Cells 6,487-494.974. Anderson, CA, Boucher, G., Lees, CW, Franke, A., D'Amato, M., Taylor, KD, Lee, JC, Goyette, P., Imielinski, M., Latiano, A., et al. (2011).Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.Nature genetics 43,246-252. V.Badot et al.,Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines.J Cell Mol Med 15,2335-2342(2011). V.Badot et al.,Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus.Ann Rheum Dis 72,453-456(2013). Barrett,J.C.,Clayton,D.G.,Concannon,P.,Akolkar,B.,Cooper,J.D.,Erlich,H.A.,Julier,C.,Morahan,G.,Nerup,J.,Nierras,C.,et al.(2009).Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.Nature genetics 41,703-707. Cheong,K.Y.,Allcock,R.J.,Eerligh,P.,Witt,C.S.,Christiansen,F.T.,McCann,V.,and Price,P.(2001).Localization of central MHC genes influencing type I diabetes.Human immunology 62,1363-1370. Degli-Esposti,M.A.,Leelayuwat,C.,and Dawkins,R.L.(1992).Ancestral haplotypes carry haplotypic and haplospecific polymorphisms of BAT1:possible relevance to autoimmune disease.Eur J Immunogenet 19,121-127. Evsyukova,I.,Bradrick,S.S.,Gregory,S.G.,and Garcia-Blanco,M.A.(2013).Cleavage and polyadenylation specificity factor 1(CPSF1)regulates alternative splicing of interleukin 7 receptor(IL7R)exon 6.RNA 19,103-115. Galarza-Munoz,G.,Briggs,F.B.,Evsyukova,I.,Schott-Lerner,G.,Kennedy,E.M.,Nyanhete,T.,Wang,L.,Bergamaschi,L.,Widen,S.G.,Tomaras,G.D.,et al.(2017).Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk.Cell 169,72-84 e13. Gregory,S.G.,Schmidt,S.,Seth,P.,Oksenberg,J.R.,Hart,J.,Prokop,A.,Caillier,S.J.,Ban,M.,Goris,A.,Barcellos,L.F.,et al.(2007).Interleukin 7 receptor alpha chain(IL7R)shows allelic and functional association with multiple sclerosis.Nature genetics 39,1083-1091. Kilding,R.,Iles,M.M.,Timms,J.M.,Worthington,J.,and Wilson,A.G.(2004).Additional genetic susceptibility for rheumatoid arthritis telomeric of the DRB1 locus.Arthritis and rheumatism 50,763-769. B.R.Lauwerys,S.N.Husson,A.L.Maudoux,V.Badot,F.A.Houssiau,sIL7R concentrations in the serum reflect disease activity in the lupus kidney.Lupus Sci Med 1,e000036(2014). Lundstrom,W.,Highfill,S.,Walsh,S.T.,Beq,S.,Morse,E.,Kockum,I.,Alfredsson,L.,Olsson,T.,Hillert,J.,and Mackall,C.L.(2013).Soluble IL7Ralpha potentiates IL-7 bioactivity and promotes autoimmunity.Proceedings of the National Academy of Sciences of the United States of America 110,E1761-1770. Maraskovsky,E.,Teepe,M.,Morrissey,P.J.,Braddy,S.,Miller,R.E.,Lynch,D.H.,and Peschon,J.J.(1996).Impaired survival and proliferation in IL-7 receptor-deficient peripheral T cells.Journal of immunology 157,5315-5323. F.C.McKay et al.,Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis.Genes Immun 9,1-6(2008). P.Monti,C.Brigatti,M.Krasmann,A.G.Ziegler,E.Bonifacio,Concentration and activity of the soluble form of the interleukin-7 receptor alpha in type 1 diabetes identifies an interplay between hyperglycemia and immune function.Diabetes 62,2500-2508(2013). Nakamura,M.,Nishida,N.,Kawashima,M.,Aiba,Y.,Tanaka,A.,Yasunami,M.,Nakamura,H.,Komori,A.,Nakamuta,M.,Zeniya,M.,et al.(2012).Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population.American journal of human genetics 91,721-728. Okamoto,K.,Makino,S.,Yoshikawa,Y.,Takaki,A.,Nagatsuka,Y.,Ota,M.,Tamiya,G.,Kimura,A.,Bahram,S.,and Inoko,H.(2003).Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis.American journal of human genetics 72,303-312. Paternoster,L.,Standl,M.,Chen,C.M.,Ramasamy,A.,Bonnelykke,K.,Duijts,L.,Ferreira,M.A.,Alves,A.C.,Thyssen,J.P.,Albrecht,E.,et al.(2012).Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis.Nature genetics 44,187-192. Peschon,J.J.,Morrissey,P.J.,Grabstein,K.H.,Ramsdell,F.J.,Maraskovsky,E.,Gliniak,B.C.,Park,L.S.,Ziegler,S.F.,Williams,D.E.,Ware,C.B.,et al.(1994).Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.J Exp Med 180,1955-1960. Price,P.,Wong,A.M.,Williamson,D.,Voon,D.,Baltic,S.,Allcock,R.J.,Boodhoo,A.,and Christiansen,F.T.(2004).Polymorphisms at positions -22 and -348 in the promoter of the BAT1 gene affect transcription and the binding of nuclear factors.Human molecular genetics 13,967-974. Puel,A.,Ziegler,S.F.,Buckley,R.H.,and Leonard,W.J.(1998).Defective IL7R expression in T(-)B(+)NK(+)severe combined immunodeficiency.Nature genetics 20,394-397. Quinones-Lombrana,A.,Lopez-Soto,A.,Ballina-Garcia,F.J.,Alperi-Lopez,M.,Queiro-Silva,R.,Lopez-Vazquez,A.,Lopez-Larrea,C.,and Gonzalez,S.(2008).BAT1 promoter polymorphism is associated with rheumatoid arthritis susceptibility.J Rheumatol 35,741-744. Roifman,C.M.,Zhang,J.,Chitayat,D.,and Sharfe,N.(2000).A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency.Blood 96,2803-2807. Todd,J.A.,Walker,N.M.,Cooper,J.D.,Smyth,D.J.,Downes,K.,Plagnol,V.,Bailey,R.,Nejentsev,S.,Field,S.F.,Payne,F.,et al.(2007).Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.Nature genetics 39,857-864. Wong,A.M.,Allcock,R.J.,Cheong,K.Y.,Christiansen,F.T.,and Price,P.(2003).Alleles of the proximal promoter of BAT1,a putative anti-inflammatory gene adjacent to the TNF cluster,reduce transcription on a disease-associated MHC haplotype.Genes Cells 8,403-412.

Claims

1. 1. A composition for use in a method of treating a disease or condition associated with high levels of a soluble isoform of interleukin-7 receptor (sIL7R) in a subject in need thereof, comprising an oligonucleotide that specifically binds to a sequence of interleukin-7 receptor (IL7R) pre-mRNA that affects splicing of exon 6, the oligonucleotide increases the inclusion of exon 6 in the IL7R pre-mRNA and reduces the expression of the soluble isoform of IL7R (sIL7R); The oligonucleotide is complementary to any one or any combination of SEQ ID NOs: 1 to 13, or any portion thereof; composition.

2. The composition of claim 1, wherein the oligonucleotide is a splice regulatory antisense oligonucleotide (SM-ASO).

3. 2. The composition of claim 1, wherein the oligonucleotide specifically binds to a sequence in the IL7R pre-mRNA in at least one of the group consisting of an exonic splicing suppressor sequence (ESS) and / or an intronic splicing suppressor sequence (ISS), thereby enhancing inclusion of exon 6 in the IL7R pre-mRNA and reducing expression of sIL7R.

4. At least one or more nucleotides in the oligonucleotide are selected from the group consisting of one or more phosphorothioate, dithiophosphate, phosphodiester, methyl phosphonate, phosphoramidate, methyl phosphonate, phosphotriester, phosphoroalidate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbones, locked nucleic acid backbones, peptide backbones, phosphotriester backbones, phosphoramidate backbones, siloxane backbones, carboxymethyl ester backbones, acetamidate backbones, carbamate backbones, thioether backbones, bridged methylene phosphonate backbones, phosphorothioate backbones, methyl phosphonate backbones, alkyl phosphonate backbones, phosphate ester backbones, methyl ...

2. The composition of claim 1, comprising a partially or fully modified backbone, such as a phosphate backbone, an alkyl phosphonothioate backbone, a phosphorodithioate backbone, a carbonate backbone, a phosphate triester backbone, a carboxymethyl ester backbone, a methyl phosphorothioate backbone, a phosphorodithioate backbone, a backbone having a p-ethoxy linkage; a sugar modification, such as 2'-O-methyl (2'-O-methyl nucleotide), 2'-O-methyloxyethoxy (2'-O-MOE), a 2'-O-alkyl modified sugar moiety, or a bicyclic sugar moiety; a non-naturally occurring modification comprising a modification or replacement of (1) the ribose or other sugar unit, (2) the base, or (3) the backbone, selected from: a nucleotide mimetic, a peptide nucleic acid (PNA), a morpholino nucleic acid, a cyclohexenyl nucleic acid, an anhydrohexitol nucleic acid, a glycol nucleic acid, a threose nucleic acid, and a locked nucleic acid (LNA), and any combination of two or more of any of the foregoing.

5. The composition of claim 1 , wherein at least one or more nucleotides in the oligonucleotide comprises a non-naturally occurring modification to the nucleotide base.

6. The composition of claim 1 , wherein the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier.

7. The composition of claim 1, wherein the disease or condition is an autoimmune disorder selected from at least one of the following: multiple sclerosis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, ankylosing spondylitis, primary biliary cirrhosis, or inflammatory bowel syndromes such as ulcerative colitis and Crohn's disease, or any other condition in which sIL7R is elevated compared to normal subjects without the disease or condition.

8. The composition of claim 1 , wherein the disease or condition is an inflammatory disease or condition.

9. 2. The composition of claim 1, wherein the oligonucleotide enhances degradation of an IL7R mRNA lacking exon 6 by targeting the IL7R exon 5 to exon 7 boundary.

10. 3. The composition of claim 2, wherein the method further comprises combination therapy of the SM-ASO with one or more active agents effective to treat a disease or condition that is an autoimmune or inflammatory disease selected from at least one of mitoxatrone, interferon beta 1a, PEG-interferon beta 1a, azathioprine, fingolimod, natalizumab, methylprednisolone, or ocrelizumab.

11. 2. The composition of claim 1, wherein the method further comprises obtaining cells from a patient and modifying the cells to transiently or permanently express an oligonucleotide that specifically binds to a sequence in the interleukin 7 receptor (IL7R) pre-mRNA that affects splicing of exon 6.

12. A composition for use in a method for treating a disease or condition associated with elevated levels of a soluble isoform of interleukin-7 receptor (sIL7R) in a subject in need thereof, comprising: a vector expressing an oligonucleotide that specifically binds to a sequence in interleukin-7 receptor (IL7R) pre-mRNA that affects splicing of exon 6; the oligonucleotide increases the inclusion of exon 6 in the IL7R pre-mRNA and reduces the expression of the soluble isoform of IL7R (sIL7R); The oligonucleotide is complementary to any one or any combination of SEQ ID NOs: 1 to 13, or any portion thereof; composition.

13. 1. A composition comprising an oligonucleotide that is a splice-modifying antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in the pre-mRNA of the interleukin-7 receptor (IL7R) that affects splicing of exon 6, the SM-ASO increases the inclusion of exon 6 in IL7R pre-mRNA and reduces the expression of the soluble isoform of IL7R (sIL7R); The oligonucleotide is complementary to any one or any combination of SEQ ID NOs: 1 to 13, or any portion thereof; composition.

14. The composition of claim 13, wherein the SM-ASO specifically binds to a sequence in the IL7R pre-mRNA in at least one of the group consisting of an exonic splicing suppressor sequence (ESS) and / or an intronic splicing suppressor sequence (ISS), thereby enhancing inclusion of exon 6 in the IL7R pre-mRNA and reducing expression of sIL7R.

15. At least one or more nucleotides in the SM-ASO are selected from the group consisting of one or more phosphorothioate, dithiophosphate, phosphodiester, methyl phosphonate, phosphoramidate, methyl phosphonate, phosphotriester, phosphoroalidate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and / or alkylsilyl substitutes; fully modified sugar phosphate backbone, locked nucleic acid backbone, peptide backbone, phosphotriester backbone, phosphoramidate backbone, siloxane backbone, carboxymethyl ester backbone, acetamidate backbone, carbamate backbone, thioether backbone, bridged methylene phosphonate backbone, phosphorothioate backbone, methyl phosphonate backbone, alkyl phosphonate backbone, phosphate ester backbone, methyl phosphorothioate backbone, 14. The composition of claim 13, comprising a partially or fully modified backbone, such as an alkyl phosphonothioate backbone, a phosphorodithioate backbone, a carbonate backbone, a phosphate triester backbone, a carboxymethyl ester backbone, a methyl phosphorothioate backbone, a phosphorodithioate backbone, a backbone having p-ethoxy linkages; a sugar modification, such as 2'-O-methyl (2'-O-methyl nucleotide), 2'-O-methyloxyethoxy (2'-O-MOE), a 2'-O-alkyl modified sugar moiety, or a bicyclic sugar moiety; a nucleotide mimetic, a peptide nucleic acid (PNA), a morpholino nucleic acid, a cyclohexenyl nucleic acid, an anhydrohexitol nucleic acid, a glycol nucleic acid, a threose nucleic acid, and a locked nucleic acid (LNA), and any combination of two or more of any of the foregoing.

16. The composition of claim 13, wherein at least one or more nucleotides in the SM-ASO comprises a non-naturally occurring modification to the nucleotide base.

17. The composition of claim 13 , wherein the composition further comprises a pharma- ceutically acceptable excipient, salt, or carrier.

18. The composition of claim 13, suitable for the treatment of an autoimmune disorder selected from at least one of the following: multiple sclerosis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, ankylosing spondylitis, primary biliary cirrhosis, or inflammatory bowel syndromes such as ulcerative colitis and Crohn's disease, or any other condition in which sIL7R is elevated.

19. The composition of claim 13, wherein the oligonucleotide enhances degradation of an IL7R mRNA lacking exon 6 by targeting the IL7R exon 5 to exon 7 boundary.

20. A composition comprising a vector expressing an oligonucleotide that is a splice-modifying antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in the pre-mRNA of the interleukin-7 receptor (IL7R) that affects splicing of exon 6, the SM-ASO increases the inclusion of exon 6 in IL7R pre-mRNA and reduces the expression of the soluble isoform of IL7R (sIL7R); The oligonucleotide is complementary to any one or any combination of SEQ ID NOs: 1 to 13, or any portion thereof; composition.

21. 1. A composition for use in a method for increasing inclusion of exon 6 in an interleukin 7 receptor (IL7R) pre-mRNA, comprising a splice-modifying antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in the interleukin 7 receptor (IL7R) pre-mRNA and increases inclusion of exon 6 in the IL7R pre-mRNA and reduces expression of a soluble isoform of IL7R (sIL7R); The SM-ASO is complementary to any one or any combination of SEQ ID NOs: 1-13, or any portion thereof; composition.

22. 22. The composition of claim 21, wherein the method further comprises combination therapy of the SM-ASO with one or more active agents effective for treating an autoimmune or inflammatory disease selected from mitoxatrone, interferon beta 1a, PEG-interferon beta 1a, azathioprine, fingolimod, natalizumab, methylprednisolone, or ocrelizumab.

23. The composition of claim 21, wherein the SM-ASO specifically binds to a sequence in the IL7R pre-mRNA in at least one of the group consisting of an exonic splicing suppressor sequence (ESS) and / or an intronic splicing suppressor sequence (ISS), thereby enhancing inclusion of exon 6 in the IL7R pre-mRNA and reducing expression of sIL7R.

24. A composition for use in a method for increasing inclusion of exon 6 in interleukin-7 receptor (IL7R) pre-mRNA, comprising a vector expressing a splice-modifying antisense oligonucleotide (SM-ASO) that specifically binds to a sequence in interleukin-7 receptor (IL7R) pre-mRNA and increases inclusion of exon 6 in the IL7R pre-mRNA and reduces expression of a soluble isoform of IL7R (sIL7R); The SM-ASO is complementary to any one or any combination of SEQ ID NOs: 1-13, or any portion thereof; composition.

25. The composition of claim 24 , wherein the vector is an expression vector.

26. The composition of claim 24 , wherein the vector is a viral vector or a plasmid.

27. The composition of claim 24 for use in gene therapy to treat a patient.

Citation Information

Patent Citations

  • Primer composition for primary immunodeficiency disease gene screening and kit using the same

    CN104131095A

  • Methods and compositions for correlating genetic markers with multiple sclerosis

    US20090035778A1

  • Materials and methods for treatment of severe combined immunodeficiency (SCID) or omenn syndrome

    WO2017141109A1